PubMed İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://acikerisim2.beykoz.edu.tr/handle/20.500.12879/5

Browse

Now showing 1 - 5 of 5

Comparing Cognitive Behavioral Therapy and Ericksonian Hypnotherapy for Obsessive–Compulsive Disorder: A Randomized Controlled Trial
(Routledge, 2026) Çınaroğlu M.; Yılmazer E.; Odabaşı C.; Ülker S.V.; Tan S.; Hızlı Sayar G.
Obsessive–Compulsive Disorder (OCD) is a chronic condition that often responds well to Cognitive Behavioral Therapy (CBT), though many patients fail to achieve full remission. Ericksonian Hypnotherapy (EH) has been proposed as a promising alternative. This randomized controlled trial compared the efficacy of CBT and EH against a waitlist control in 99 adults with OCD. Participants received 12 weekly online therapy sessions. Outcomes were assessed at baseline, mid-treatment, and post-treatment using the Padua Inventory-Revised, Yale–Brown Obsessive Compulsive Scale–Self-Report (Y-BOCS-SR), and Beck Anxiety Inventory (BAI). Both CBT and EH led to large, statistically and clinically significant reductions in OCD symptoms compared to waitlist. CBT was more effective for compulsive behaviors such as washing, while EH produced greater reductions in obsessive rumination and general anxiety. No serious adverse events occurred. These findings suggest that EH is a viable and comparably effective treatment to CBT, with distinct therapeutic benefits. EH may offer a particularly useful option for patients with obsession-dominant symptom profiles or comorbid anxiety. © 2026 International Journal of Clinical and Experimental Hypnosis.
Discriminant Analysis Using MRI Asymmetry Indices and Cognitive Scores of Women with Temporal Lobe Epilepsy or Schizophrenia
(Springer Science and Business Media Deutschland GmbH, 2024) Fırat, Z.; Er, F.; Noyan, H.; Ekinci, G.; Üçok, A.; Ulǔg, A.M.; Aktekin, B.
Purpose: This study aims to assess the diagnostic power of brain asymmetry indices and neuropsychological tests for differentiating mesial temporal lobe epilepsy (MTLE) and schizophrenia (SCZ). Methods: We studied a total of 39 women including 13 MTLE, 13 SCZ, and 13 healthy individuals (HC). A neuropsychological test battery (NPT) was administered and scored by an experienced neuropsychologist, and NeuroQuant (CorTechs Labs Inc., San Diego, California) software was used to calculate brain asymmetry indices (ASI) for 71 different anatomical regions of all participants based on their 3D T1 MR imaging scans. Results: Asymmetry indices measured from 10 regions showed statistically significant differences between the three groups. In this study, a multi-class linear discriminant analysis (LDA) model was built based on a total of fifteen variables composed of the most five significantly informative NPT scores and ten significant asymmetry indices, and the model achieved an accuracy of 87.2%. In pairwise classification, the accuracy for distinguishing MTLE from either SCZ or HC was 94.8%, while the accuracy for distinguishing SCZ from either MTLE or HC was 92.3%. Conclusion: The ability to differentiate MTLE from SCZ using neuroradiological and neuropsychological biomarkers, even within a limited patient cohort, could make a substantial contribution to research in larger patient groups using different machine learning techniques. © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024.
Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants with Treatment Resistance in Schizophrenia
(American Medical Association, 2022) Pardiñas, A.F.; Smart, S.E.; Willcocks, I.R.; Holmans, P.A.; Dennison, C.A.; Lynham, A.J.; Legge, S.E.
Importance: About 20% to 30% of people with schizophrenia have psychotic symptoms that do not respond adequately to first-line antipsychotic treatment. This clinical presentation, chronic and highly disabling, is known as treatment-resistant schizophrenia (TRS). The causes of treatment resistance and their relationships with causes underlying schizophrenia are largely unknown. Adequately powered genetic studies of TRS are scarce because of the difficulty in collecting data from well-characterized TRS cohorts. Objective: To examine the genetic architecture of TRS through the reassessment of genetic data from schizophrenia studies and its validation in carefully ascertained clinical samples. Design, Setting, and Participants: Two case-control genome-wide association studies (GWASs) of schizophrenia were performed in which the case samples were defined as individuals with TRS (n = 10501) and individuals with non-TRS (n = 20325). The differences in effect sizes for allelic associations were then determined between both studies, the reasoning being such differences reflect treatment resistance instead of schizophrenia. Genotype data were retrieved from the CLOZUK and Psychiatric Genomics Consortium (PGC) schizophrenia studies. The output was validated using polygenic risk score (PRS) profiling of 2 independent schizophrenia cohorts with TRS and non-TRS: a prevalence sample with 817 individuals (Cardiff Cognition in Schizophrenia [CardiffCOGS]) and an incidence sample with 563 individuals (Genetics Workstream of the Schizophrenia Treatment Resistance and Therapeutic Advances [STRATA-G]). Main Outcomes and Measures: GWAS of treatment resistance in schizophrenia. The results of the GWAS were compared with complex polygenic traits through a genetic correlation approach and were used for PRS analysis on the independent validation cohorts using the same TRS definition. Results: The study included a total of 85490 participants (48635 [56.9%] male) in its GWAS stage and 1380 participants (859 [62.2%] male) in its PRS validation stage. Treatment resistance in schizophrenia emerged as a polygenic trait with detectable heritability (1% to 4%), and several traits related to intelligence and cognition were found to be genetically correlated with it (genetic correlation, 0.41-0.69). PRS analysis in the CardiffCOGS prevalence sample showed a positive association between TRS and a history of taking clozapine (r2 = 2.03%; P =.001), which was replicated in the STRATA-G incidence sample (r2 = 1.09%; P =.04). Conclusions and Relevance: In this GWAS, common genetic variants were differentially associated with TRS, and these associations may have been obscured through the amalgamation of large GWAS samples in previous studies of broadly defined schizophrenia. Findings of this study suggest the validity of meta-analytic approaches for studies on patient outcomes, including treatment resistance. © 2022 Pardiñas AF et al.
Particulate and Non-Particle Adjuvants in Leishmaniasis Vaccine Designs: A Review
(Wolters Kluwer Medknow Publications, 2023) Kelleci, Kubra; Allahverdiyev, Adil; Bagirova, Melahat; Ihlamur, Murat; Abamor, Emrah S.
Leishmaniasis is a parasitic disease with different clinical forms caused by protozoan parasites of the genus Leishmania and transmitted by the bite of an infected female sandfly. According to the World Health Organization (WHO), it is the second most common parasitic disease after malaria and it is known that approximately 350 million people are at risk. The disease manifests itself in different clinical forms. In addition to asymptomatic cases, cutaneous leishmaniasis (CL), which creates large lesions on the skin, and visceral leishmaniasis (VL), which causes death if not treated, especially affecting the abdominal organs, are two important clinical forms. When the studies were examined, it was seen that a clinically used vaccine against any form of human leishmaniasis has not been developed yet. In some studies, it was stated that the lack of appropriate adjuvant was responsible for the failure to develop an effective Leishmania vaccine. We can say that strong adjuvants are needed to achieve successful vaccines. In this article, adjuvants and adjuvant candidates used in vaccine studies against leishmaniasis are discussed
Where Can Urodynamic Testing Help Assess Male Lower Urinary Tract Symptoms
(AVES, 2019) Gurbuz, Cenk; Drake, Marcus J.
Urodynamic studies assess the function of the bladder and bladder outlet. They are often useful in the assessment and diagnosis of patients presenting with lower urinary tract symptoms (LUTS). The evidence regarding the value and risks of invasive urodynamics remains insufficient. However, men with LUTS who are assessed by invasive urodynamics are more likely to have their management changed and less likely to undergo surgery. This review discusses the role of urodynamic diagnosis and application in the diagnosis and treatment of male LUTS.

Browse

Browsing PubMed İndeksli Yayınlar Koleksiyonu by Scopus Q "N/A"